Open AccessRelationship of Adiponectin with Markers of Systemic Inflammation, Atherogenic Dyslipidemia, and Heart Failure in Patients with Coronary Heart Disease
Author(s) -
Maximilian von Eynatten,
A. Hamann,
Dorothee Twardella,
Peter P. Nawroth,
Hermann Brenner,
Dietrich Rothenbacher
Publication year - 2006
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2005.060509
Subject(s) - adiponectin , medicine , endocrinology , dyslipidemia , systemic inflammation , population , c reactive protein , body mass index , heart failure , natriuretic peptide , triglyceride , diabetes mellitus , cholesterol , insulin resistance , inflammation , environmental health
Adiponectin, an adipocyte-derived hormone, appears to be a modulator of lipid metabolism and systemic inflammation and is present in particularly low concentrations in patients with coronary heart disease (CHD). However, the clinical importance of adiponectin in individuals at markedly high risk for future cardiovascular morbidity and mortality has not been fully elucidated. We examined the associations between serum adiponectin and several biomarkers related to cardiovascular disease and heart failure in a large high-risk population comprising patients with prevalent CHD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom